The FDA has now resolved the shortages of Novo Nordisk and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

Zealand’s CEO Adam Steensberg said that the company is “exactly where it wants to be” in terms of its partnering and ...

Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...

More than 830 million people worldwide have diabetes—a chronic, debilitating disease. But experts say it’s possible to recover with a few proven lifestyle changes.

Though more research is needed to understand who might benefit from GLP-1 agonists for addiction, early studies suggest that the approach holds promise.

The truth is that muscle growth can vary widely from one person to another. Here's how to maximize yours. Ever wonder why ...

Some diets, such as plant-based and low-carbohydrate diets, can benefit hormonal health, while diets high in processed foods ...

WEIGHT loss jabs could raise the risk of a “potentially blinding condition” known as an “eye stroke”, researchers have warned ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial of its experimental drug CagriSema — a combination of semaglutide and a ...